+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07525206

Global Phase 3 Randomized Study Comparing Intravenous Telisotuzumab Adizutecan plus Bevacizumab Versus Oral TrifluridineTipiracil plus Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Led by AbbVie · Updated on 2026-10-19

990

Participants Needed

88

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and disease activity changes of telisotuzumab adizutecan combined with bevacizumab compared to the standard treatment of trifluridine and tipiracil LONSURF plus bevacizumab in adults with refractory metastatic colorectal cancer. This Phase 3 study aims to enroll about 990 participants worldwide to better understand these treatments in this patient group. Participants will be randomly assigned to one of two groups one group will receive intravenous telisotuzumab adizutecan with bevacizumab, while the other group will receive the standard of care, which includes oral trifluridine and tipiracil plus intravenous bevacizumab. Treatment will continue for approximately 36 months. During the study, participants will attend regular visits at approved hospitals or clinics where medical assessments, blood tests, questionnaires, and side effect monitoring will take place. The main outcomes measured include objective response up to 15 months and overall survival up to 36 months, with additional measures such as progression-free survival and duration of response tracked up to 24 months. This ongoing monitoring aims to understand the impact and safety of the treatments over time.

CONDITIONS

Brief Title

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here